A

Business profile & competitive position

Agilent Technologies, Inc. operates within the Healthcare sector, specifically in the Medical – Diagnostics & Research industry. The company supplies application-focused solutions for life sciences, diagnostics and applied markets, selling instruments, software, services and consumables that cover the entire laboratory workflow. After a November 2024 reorganization, Agilent now reports through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. It reaches customers primarily through a direct sales force, complemented by distributors, resellers, manufacturers’ representatives and e-commerce.

The financial footprint points to a business with meaningful operating discipline. Agilent’s net margin of 19.5% and return on equity of 20.5% are both comfortably above the mid-teens levels often seen across broad healthcare-equipment and diagnostics peers. A nearly 20% net margin suggests that pricing power, recurring services revenue and consumables pull-through are supporting profitability, while a 20.5% ROE indicates that management is generating solid returns on shareholder capital rather than relying on heavy balance-sheet leverage to inflate equity returns. The P/E ratio of 28.7 implies the market is awarding the company a premium valuation, which is consistent with a diagnostics-and-research platform whose revenue streams combine instrument placements with ongoing service and consumable attachments.

Financial posture

Agilent currently carries a market capitalization of $41.2 billion and trades at 28.7 times earnings. Against a net margin of 19.5% and ROE of 20.5%, that valuation reflects a quality-company premium rather than a deep-value setup. The beta of 1.24 signals that the stock has historically moved about 24% more than the overall market, so price swings around earnings, sector rotations or macro shocks can be amplified relative to the S&P 500.

The current snapshot shows the stock at $145.83, with the 50-day exponential moving average at $144.00 and the RSI at 46.0. That RSI reading sits near neutral territory, neither overbought nor oversold, while the price is only modestly above its 50-day EMA. For a trader evaluating near-term momentum, this suggests a relatively balanced technical setup rather than an extreme positioning condition.

Strategic priorities & outlook

Agilent’s most recent SEC 10-K filing describes three strategic pillars that frame its near-term operational focus. The first is organizational: the company reorganized into the three reportable segments to support a market-focused, customer-centric strategy, making it easier to align R&D and commercial resources with distinct end markets. The second is product-led expansion: Agilent intends to broaden the liquid chromatography application space through new columns, new services and ongoing instrument-and-software enhancements, while also improving its mass-spectrometry portfolio across performance, sensitivity, precision, robustness, ease of use and onboard intelligence. The third pillar is digital and services growth: the company is advancing software and service solutions to help customers build digitally connected “smart labs” that leverage data analytics, artificial intelligence and robotics.

Operationally, Agilent employed approximately 18,100 people worldwide as of October 31, 2025, with the largest segmental headcount in Agilent CrossLab at about 7,400 employees. The business runs on centralized order fulfillment and supply-chain operations, backed by a global infrastructure organization that provides shared finance, IT, legal, procurement, workplace and HR services. Its primary R&D and manufacturing sites span California, Colorado, Delaware, Massachusetts, Texas and Vermont in the U.S., plus international locations in Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom.

Macro & geopolitical exposure

As a Healthcare / Medical – Diagnostics & Research company with a global manufacturing footprint, Agilent faces several macro and geopolitical sensitivities. First, the diagnostics and analytical-instrument industry is exposed to supply-chain and trade-policy risk: instruments and components move across borders, and tariffs or export controls can affect both production costs and customer capital-expenditure cycles. Second, regulation is inherent to the industry. Diagnostic products, laboratory instruments and associated software must meet quality and approval standards in the U.S., EU and other major markets, so changes in FDA, CE-IVD or other regulatory frameworks can influence product launch timelines and compliance costs. Third, the business is tied to biopharma and academic research budgets, which in turn are sensitive to interest rates, government funding and the broader health of the life-science end market. Fourth, with sales and facilities spread across regions including China, Europe and Southeast Asia, foreign-exchange volatility can impact translated revenue and margin.

Recent developments

Over the first half of September 2026, Agilent generated a mix of investor-activity and corporate-governance headlines. On September 14, 2026, defenseworld.net reported that Corient Private Wealth LP had boosted its holdings in the company. Two days earlier, on September 10, 2026, businesswire.com announced that Agilent would participate in the J.P. Morgan U.S. All Stars Conference, giving management a forum to discuss strategy and outlook with institutional investors. The same day, defenseworld.net noted that the Arizona State Retirement System had increased its stock position in Agilent. On September 8, 2026, businesswire.com reported a board change: Board Chair Koh Boon Hwee was retiring, and Glenn Boehnlein was appointed to the board of directors. Taken together, these items point to continued institutional accumulation alongside a governance transition at the board level.

Earnings behavior & post-earnings drift

Agilent has delivered beats in 6 of its last 8 reported quarters, translating to a beat rate of 86%, with an average earnings surprise of 3%. Over those quarters, the average 5-day price move after the earnings release has been 2.44% to the upside. That combination—frequent beats and a positive average drift—looks like a healthy earnings record at first glance, but the underlying quarter-by-quarter path is more nuanced.

The company reports next on November 23, 2026, after the market close, with the current consensus EPS estimate at $1.72. Looking back at the four most recent quarters shows why “beat equals pop and hold” is too simple an assumption for this stock:

• August 26, 2026: EPS of $1.62 beat the $1.49 estimate by 8.7%. The stock rose 1.68% the next day but fell 2.38% over the following five sessions.
• May 27, 2026: EPS of $1.49 beat the $1.41 estimate by 5.7%. The stock jumped 16.87% the next day and extended that gain to 18.61% over five sessions.
• February 25, 2026: EPS of $1.36 missed the $1.37 estimate by 0.7%. The stock fell 3.01% the next day and drifted 3.35% lower over five sessions.
• November 24, 2025: EPS of $1.59 beat the $1.58431 estimate by 0.4%. The stock rose 2.34% the next day but gave back 3.12% over the following five sessions.

The key takeaway is that even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise. Two of the last three beats—August 2026 and November 2025—were followed by negative five-day drift, while only the May 2026 beat produced a strong follow-through. This disconnect suggests that the market’s reaction often prices in more than just the headline EPS print, incorporating guidance, margin commentary, order trends and sector sentiment.